New strategies to control the inflammatory response in cardiac surgery

Current Opinion in Anaesthesiology

Volumn 17, Issue 1, 2004, Pages 35-48

  Maharaj, Chris ^a   Laffey, John G ^a,b  

^a UNIVERSITY HOSPITAL GALWAY   (Ireland)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

Cardiac surgery; Cardiopulmonary bypass; Immunomodulation; Inflammation; Off pump coronary artery bypass; Therapy

Indexed keywords

ACRYLIC ACID DERIVATIVE; ALPHA TOCOPHEROL; ANTIINFLAMMATORY AGENT; APROTININ; BUPIVACAINE; COLCHICINE; DEXAMETHASONE; DILTIAZEM; DOPEXAMINE; ENDOTOXIN; ENDOTOXIN ANTIBODY; ENOXIMONE; HEPARIN; HYDROCORTISONE; IMMUNOGLOBULIN M; KETAMINE; METHYLPREDNISOLONE; NITROPRUSSIDE SODIUM; PLANT EXTRACT; POLY(2 METHOXYETHYLACRYLATE); POLYMER; PROPOFOL; SERINE PROTEINASE INHIBITOR; SEVOFLURANE; SIMVASTATIN; TIROFIBAN; TRILLIUM EXTRACT; UNCLASSIFIED DRUG;

ANASTOMOSIS; AORTA CLAMPING; ASSISTED CIRCULATION; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD OXYGEN TENSION; BLOOD OXYGENATION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; CLINICAL TRIAL; COGNITIVE DEFECT; COMPLEMENT ACTIVATION; CYTOKINE RELEASE; DRUG COATING; DRUG EFFECT; DRUG EFFICACY; ENDOTOXEMIA; ENTERIC FEEDING; ERYTHROCYTE TRANSFUSION; EXTRACORPOREAL CIRCULATION; FIBRINOLYSIS; GRAFT PATENCY; HEART GRAFT; HEART MUSCLE INJURY; HEART MUSCLE PERFUSION; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEMODYNAMIC MONITORING; HEMOFILTRATION; HEPARINIZATION; HIGH RISK POPULATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOMODULATION; INFLAMMATION; LENGTH OF STAY; LEUKAPHERESIS; LEUKOCYTE ACTIVATION; LUNG ALVEOLUS OXYGEN TENSION; LUNG INJURY; OFF PUMP CORONARY SURGERY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVASCULARIZATION; REVIEW; SPLANCHNIC BLOOD FLOW; SURGICAL TECHNIQUE; SURVIVAL RATE; THROMBOCYTE ACTIVATION; THROMBOCYTOPHERESIS; TRILLIUM; ULTRAFILTRATION;

EID: 1342343895     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200402000-00007     Document Type: Review

References (51)

1. Puskas JD, Williams WH, Duke PG, et al. Off-pump coronary artery bypass grafting provides complete revascularization with reduced myocardial injury, transfusion requirements, and length of stay, a prospective randomized comparison of two hundred unselected patients undergoing off-pump versus conventional coronary artery bypass grafting. J Thorac Cardiovasc Surg 2003; 125:797-808. An excellent clinical trial demonstrating that OPCAB results in a comparable extent of revascularization, and an improved early postoperative clinical profile compared with conventional CABG with CBP in low-risk patients.
2. Nathoe HM, van Dijk D, Jansen EW, et al. A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients. N Engl J Med 2003; 348:394-402. An excellent clinical trial demonstrating that revascularization with OPCAB results in comparable exercise tolerance and one-year graft patency rates to conventional CABG with CBP in low-risk patients. This paper provides considerable reassurance regarding the quality of revascularization achieved with OPCAB.
3. Caputo M, Yeatman M, Narayan P, et al. Effect of off-pump coronary surgery with right ventricular assist device on organ function and inflammatory response: a randomized controlled trial. Ann Thorac Surg 2002; 74:2088-2095. A well-conducted clinical trial demonstrating that OPCAB attenuates the indices of organ injury and improves the early postoperative clinical profile compared with conventional CABG with CBP in low-risk patients. There was no added benefit of the use of RVADs.
4. Meyns B, Autschbach R, Boning A, et al. Coronary artery bypass grafting supported with intracardiac microaxial pumps versus normothermic cardiopulmonary bypass: a prospective randomized trial. Eur J Cardiothorac Surg 2002; 22:112-117. A good clinical trial demonstrating the feasibility and safety of OPCAB with microaxial pumps, which are safe when compared with conventional CABG with CBP in low-risk patients.
5. Inoue T, Ku K, Kaneda T, et al. Cardioprotective effects of lowering oxygen tension after aortic unclamping on cardiopulmonary bypass during coronary artery bypass grafting. Circ J 2002; 66:718-722. A highly original clinical trial demonstrating that reperfusion post-aortic unclamping at lower oxygen tension may have protective effects in patients undergoing CPB.
6. Sievers HH, Freund-Kaas C, Eleftheriadis S, et al. Lung protection during total cardiopulmonary bypass by isolated lung perfusion: preliminary results of a novel perfusion strategy. Ann Thorac Surg 2002; 74:1167-1172. An original, preliminary clinical trial demonstrating that hypothermic lung perfusion during CPB may reduce inflammation and acute lung injury in patients undergoing CPB.
7. Lindholm L, Bengtsson A, Hansdottir V, et al. Regional oxygenation and systemic inflammatory response during cardiopulmonary bypass: influence of temperature and blood flow variations. J Cardiothorac Vasc Anesth 2003; 17:182-187.
8. Laffey JG, Boylan JF, Cheng DC. The systemic inflammatory response to cardiac surgery: implications for the anesthesiologist. Anesthesiology 2002; 97:215-252.
9. Kalawski R, Majewski M, Kaszkowiak E, et al. Transcardiac release of soluble adhesion molecules during coronary artery bypass grafting: effects of crystalloid and blood cardioplegia. Chest 2003; 123:1355-1360.
10. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: impact of heparin management. Anesthesiology 2002; 97:837-841. An interesting, well-conducted clinical trial demonstrating that heparin management may modulate the inflammatory response in patients undergoing CPB.
11. Wildevuur CR, Jansen PG, Bezemer PD, et al. Clinical evaluation of Duraflo II heparin treated extracorporeal circulation circuits (2nd version). The European Working Group on heparin coated extracorporeal circulation circuits. Eur J Cardiothorac Surg 1997; 11:616-623.
12. Ranucci M, Mazzucco A, Pessotto R, et al. Heparin-coated circuits for high-risk patients: a multicenter, prospective, randomized trial. Ann Thorac Surg 1999; 67:994-1000.
13. Svenmarker S, Haggmark S, Jansson E, et al. Use of heparin-bonded circuits in cardiopulmonary bypass improves clinical outcome. Scand Cardiovasc J 2002; 36:241-246. This important paper aggregates data from two previous HCC studies and demonstrates that HCCs improve short-term clinical outcome but not 5-year survival in low-risk patients undergoing CPB.
14. Butler J, Murithi EW, Pathi VL, et al. Duroflo II heparin bonding does not attenuate cytokine release or improve pulmonary function. Ann Thorac Surg 2002; 74:139-142.
15. Palatianos GM, Foroulis CN, Vassili MI, et al. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 2003; 76:129-135. A well-conducted clinical trial demonstrating that the bioline HCC may modulate the inflammatory response and confer some clinical benefit in low-risk patients undergoing CPB.
16. Johnell M, Elgue G, Larsson R, et al. Coagulation, fibrinolysis, and cell activation in patients and shed mediastinal blood during coronary artery bypass grafting with a new heparin-coated surface. J Thorac Cardiovasc Surg 2002; 124:321-332.
17. Jensen E, Andreasson S, Bengtsson A, et al. Influence of two different perfusion systems on inflammatory response in pediatric heart surgery. Ann Thorac Surg 2003; 5:919-925.
18. Fromes Y, Gaillard D, Ponzio O, et al. Reduction of the inflammatory response following coronary bypass grafting with total minimal extracorporeal circulation. Eur J Cardiothorac Surg 2002; 22:527-533. An interesting, small clinical trial demonstrating that a minimized extracorporeal circuit may attenuate the inflammatory response in patients undergoing CPB.
19. Ninomiya M, Miyaji K, Takamoto S. Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg 2003; 75:913-917.
20. Gunaydin S, Farsak B, Kocakulak M, et al. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)-coated extracorporeal circuits. Ann Thorac Surg 2002; 74:819-824. An interesting, small clinical trial demonstrating that a poly(2-methoxyethylacrylate)-coated oxygenator may attenuate the inflammatory response and confer clinical benefit in patients undergoing CPB.
21. Dickinson T, Mahoney CB, Simmons M, et al. Trillium-coated oxygenators in adult open-heart surgery: a prospective randomized trial. J Extra-Corpor Technol 2002; 34:248-253.
22. Mathew JP, Grocott HP, Phillips-Bute B, et al. Lower endotoxin immunity predicts increased cognitive dysfunction in elderly patients after cardiac surgery. Stroke 2003; 34:508-513. An important clinical study demonstrating that a lowered preoperative endotoxin immunity predicts an increased risk of cognitive dysfunction post-CPB, especially among older patients.
23. Aydin NB, Gercekoglu H, Aksu B, et al. Endotoxemia in coronary artery bypass surgery: a comparison of the off-pump technique and conventional cardiopulmonary bypass. J Thorac Cardiovasc Surg 2003; 125:843-848.
24. Bolke E, Orth K, Jehle PM, et al. Enterai application of an immunoglobulin-enriched colostrum milk preparation for reducing endotoxin translocation and acute phase response in patients undergoing coronary bypass surgery - a randomized placebo-controlled pilot trial. Wien Klin Wochenschr 2002; 114:923-928.
25. Bennett-Guerrero E, Panah MH, Bodian CA, et al. Automated detection of gastric luminal partial pressure of carbon dioxide during cardiovascular surgery using the Tonocap. Anesthesiology 2000; 92:38-45.
26. Boldt J, Brosch C, Suttner S, et al. Prophylactic use of the phosphodiesterase III inhibitor enoximone in elderly cardiac surgery patients: effect on hemodynamics, inflammation, and markers of organ function. Intens Care Med 2002; 28:1462-1469. An interesting, small clinical trial demonstrating that perioperative Enoximone therapy may attenuate the inflammatory response and confer clinical benefit in elderly patients undergoing CPB.
27. Bach F, Grundmann U, Bauer M, et al. Modulation of the inflammatory response to cardiopulmonary bypass by dopexamine and epidural anesthesia. Acta Anaesthesiol Scand 2002; 46:1227-1235.
28. Gol MK, Nisanoglu V, Iscan Z, et al. Inhibition of systemic inflammatory response with sodium nitroprusside in open heart surgery. J Cardiovasc Surg (Torino) 2002; 43:803-809.
29. Fansa I, Gol M, Nisanoglu V, et al. Does diltiazem inhibit the inflammatory response in cardiopulmonary bypass? Med Sci Monit 2003; 9:P130-P136.
30. Chew MS, Brix-Christensen V, Ravn HB, et al. Effect of modified urtrafiltration on the inflammatory response in paediatric open-heart surgery: a prospective, randomized study. Perfusion 2002; 17:327-333. An interesting, small clinical trial demonstrating that modified ultrafiltration may improve postoperative clinical profile but does not attenuate the inflammatory response in children undergoing CPB for congenital heart surgery.
31. Wallis JP, Chapman CE, Orr KE, et al. Effect of WBC reduction of transfused RBCs on postoperative infection rates in cardiac surgery. Transfusion 2002; 42:1127-1134. An important, large-scale clinical trial demonstrating that leukocyte reduction of transfused RBCs may decrease the postoperative infection rate in low-risk patients undergoing cardiac surgery with CPB.
32. Scholz M, Simon A, Matheis G, et al. Leukocyte filtration fails to limit functional neutrophil activity during cardiac surgery. Inflamm Res 2002; 51:363-368.
33. Fattorutto M, Pradier O, Jansens JL, et al. Plateletpheresis the day before cardiac surgery and the impairment of platelet function. Eur J Anaesthesiol 2003; 20:338-340.
34. Levi M, Cromheecke ME, de Jonge E, et al. Pharmacological strategies to decrease excessive blood loss in cardiac surgery:a meta-analysis of clinically relevant endpoints. Lancet 1999; 354:1940-1947.
35. Schmartz D, Tabardel Y, Preiser JC, et al. Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients? J Thorac Cardiovasc Surg 2003; 125:184-190.
36. Mossinger H, Dietrich W, Braun SL, et al. High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. Ann Thorac Surg 2003; 75:430-437. A well-conducted, small clinical trial demonstrating that aprotinin improves the postoperative clinical profile but has limited anti-inflammatory activity in children undergoing CPB for congenital heart surgery.
37. Broche F, Romero A, Olembe E, et al. Aprotinin mediated antioxidant effect in cardiosurgery with mechanical cardiorespiratory support (CMCS). J Cardiovasc Surg (Torino) 2002; 43:429-436. A small non-randomized clinical trial demonstrating that aprotinin inhibits free radical generation in high-risk children undergoing CPB for congenital heart surgery.
38. Julier K, da Silva R, Garcia C, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology 2003; 98:1315-1327. An interesting clinical trial demonstrating that pharmacological preconditioning with sevoflurane may attenuate myocardial and renal dysfunction in low-risk patients undergoing cardiac surgery with CPB.
39. De Hert SG, ten Broecke PW, Mertens E, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology 2002; 97:42-49. A preliminary study demonstrating that sevoflurane anaesthesia preserves myocardial function and reduces injury compared with propofol in low-risk patients undergoing cardiac surgery with CPB.
40. Zilberstein G, Levy R, Rachinsky M, et al. Ketamine attenuates neutrophil activation after cardiopulmonary bypass. Anesth Analg 2002; 95:531-536.
41. Koster A, Chew DP, Kuebler W, et al. Effects of tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass. Am J Cardiol 2003; 91:346-347. An interesting preliminary clinical trial demonstrating that tirofiban attenuates haemostatic dysfunction and inflammation in low-risk patients undergoing cardiac surgery with CPB.
42. Lassnigg A, Punz A, Barker R, et al. Influence of intravenous vitamin E supplementation in cardiac surgery on oxidative stress: a double-blinded, randomized, controlled study. Br J Anaesth 2003; 90:148-154.
43. Finkelstein Y, Shemesh J, Mahlab K, et al. Colchicine for the prevention of postpericardiotomy syndrome. Herz 2002; 27:791-794.
44. Kilger E, Weis F, Briegel J, et al. Stress doses of hydrocortisone reduce severe systemic inflammatory response syndrome and improve early outcome in a risk group of patients after cardiac surgery. Crit Care Med 2003; 31:1068-1074. An important, well-conducted, clinical trial demonstrating that hydrocortisone attenuates the inflammatory response and improves the postoperative clinical profile in high-risk patients undergoing cardiac surgery with CPB.
45. Schroeder VA, Pearl JM, Schwartz SM, et al. Combined steroid treatment for congenital heart surgery improves oxygen delivery and reduces postbypass inflammatory mediator expression. Circulation 2003; 107:2823-2828 An interesting, well-conducted clinical trial demonstrating the attenuation of the inflammatory response with combined preoperative and intraoperative methylprednisolone in paediatric cardiac surgery.
46. Varan B, Tokel K, Mercan S, et al. Systemic inflammatory response related to cardiopulmonary bypass and its modification by methyl prednisolone: high dose versus low dose. Pediatr Cardiol 2002; 23:437-441.
47. Checchia PA, Backer CL, Bronicki RA, et al. Dexamethasone reduces postoperative troponin levels in children undergoing cardiopulmonary bypass. Crit Care Med 2003; 31:1742-1745.
48. Lindberg L, Forsell C, Jogi P, Olsson AK. Effects of dexamethasone on clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen after paediatric cardiac surgery. Br J Anaesth 2003; 90:728-732.
49. Fitch JC, Rollins S, Matis L, et al. Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass. Circulation 1999; 100:2499-2506.
50. Friedrich I, Silber RE, Baumann B, et al. IgM-enriched immunoglobulin preparation for immunoprophylaxis in cardiac surgery. Eur J Med Res 2002; 7:544-549.
51. Chello M, Mastroroberto P, Patti G, et al. Simvastatin attenuates leucocyte-endothelial interactions after coronary revascularisation with cardiopulmonary bypass. Heart 2003; 89:538-543. An important, novel study demonstrating the attenuation of neutrophil and endothelial cell adhesion molecule expression and neutrophil-endothelial interaction by simvastatin via a mechanism that appears to be independent of its cholesterol-lowering effects.